AssetMark Inc’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $2.64M | Buy |
21,001
+2,045
| +11% | +$257K | 0.01% | 714 |
|
|
2025
Q1 | $2.1M | Sell |
18,956
-958
| -5% | -$106K | 0.01% | 709 |
|
|
2024
Q4 | $2.72M | Buy |
19,914
+1,591
| +9% | +$217K | 0.01% | 641 |
|
|
2024
Q3 | $2.11M | Buy |
18,323
+1,753
| +11% | +$202K | 0.01% | 642 |
|
|
2024
Q2 | $2.28M | Buy |
16,570
+4,460
| +37% | +$614K | 0.01% | 580 |
|
|
2024
Q1 | $1.67M | Sell |
12,110
-24,845
| -67% | -$3.43M | 0.01% | 619 |
|
|
2023
Q4 | $4.87M | Buy |
36,955
+8,678
| +31% | +$1.14M | 0.02% | 376 |
|
|
2023
Q3 | $3.18M | Buy |
28,277
+4,350
| +18% | +$489K | 0.01% | 424 |
|
|
2023
Q2 | $2.26M | Buy |
23,927
+4,151
| +21% | +$391K | 0.01% | 455 |
|
|
2023
Q1 | $2M | Buy |
19,776
+1,903
| +11% | +$193K | 0.01% | 451 |
|
|
2022
Q4 | $2.13M | Buy |
17,873
+1,471
| +9% | +$176K | 0.01% | 423 |
|
|
2022
Q3 | $1.74M | Buy |
16,402
+2,929
| +22% | +$311K | 0.01% | 407 |
|
|
2022
Q2 | $1.31M | Buy |
13,473
+4,317
| +47% | +$421K | 0.01% | 435 |
|
|
2022
Q1 | $858K | Buy |
9,156
+4,093
| +81% | +$384K | ﹤0.01% | 502 |
|
|
2021
Q4 | $431K | Buy |
5,063
+3,585
| +243% | +$305K | ﹤0.01% | 568 |
|
|
2021
Q3 | $142K | Buy |
+1,478
| New | +$142K | ﹤0.01% | 612 |
|
|
2019
Q3 | – | Sell |
-12
| Closed | -$1K | – | 1382 |
|
|
2019
Q2 | $1K | Buy |
12
+2
| +20% | +$167 | ﹤0.01% | 1252 |
|
|
2019
Q1 | $1K | Sell |
10
-18
| -64% | -$1.8K | ﹤0.01% | 1261 |
|
|
2018
Q4 | $2K | Buy |
+28
| New | +$2K | ﹤0.01% | 1224 |
|
|
2018
Q1 | – | Sell |
-20
| Closed | -$2K | – | 1777 |
|
|
2017
Q4 | $2K | Buy |
20
+15
| +300% | +$1.5K | ﹤0.01% | 1463 |
|
|
2017
Q3 | $0 | Buy |
+5
| New | – | ﹤0.01% | 1568 |
|
|
2016
Q1 | – | Sell |
-15
| Closed | -$1K | – | 1336 |
|
|
2015
Q4 | $1K | Buy |
+15
| New | +$1K | ﹤0.01% | 1233 |
|